186 results on '"Mwangi, Raphael"'
Search Results
2. Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL
3. Defining primary refractory large B-cell lymphoma
4. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment
5. Beyond Atrial Fibrillation: Machine Learning Algorithm Predicts Stroke in Adult Patients With Congenital Heart Disease
6. Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience
7. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
8. Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis
9. Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
10. GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity
11. Characteristics and outcomes of incidentally diagnosed diffuse large B‐cell lymphoma and implications for cancer screening.
12. Long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system.
13. PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
14. Comparison of Incident Cardiovascular Event Rates Between Generic and Brand l-Thyroxine for the Treatment of Hypothyroidism
15. Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups
16. Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era
17. P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
18. Outcomes and Complications in the Management of Distal Radial Fractures in the Elderly
19. Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL
20. Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL
21. Trends and predictors of repeat catheter ablation for atrial fibrillation
22. Outcomes and Complications in the Management of Distal Radial Fractures in the Elderly
23. High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?
24. Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab.
25. Abstract 5222: Genetic variants associated with progression from monoclonal B-cell lymphocytosis (MBL) to chronic lymphocytic leukemia (CLL)
26. Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Study
27. Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL
28. Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis
29. Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC)
30. Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era
31. Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
32. Vaccination History and Risk of Lymphoma and Its Major Subtypes
33. Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment
34. Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma.
35. Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes
36. Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab
37. Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
38. PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts
39. Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria
40. Diagnosis to Treatment Interval (DTI) Informs Outcomes across Subtypes of Aggressive B-Cell Lymphoma
41. Lymphoid Malignancy Risk with Rare Inherited Variants in Known Cancer Predisposition Genes
42. Artificial Intelligence Derived Changes between Baseline and Interim FDG-PET/CT Radiomics Features Are Associated with Survival Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL)
43. Primary Central Nervous System Lymphoma and Contemporary Clinical Prognostication
44. Comparison of Methotrexate Maintenance Versus Autologous Stem Cell Transplant Consolidation after High-Dose Methotrexate-Based Induction Therapy in Primary Central Nervous System Lymphoma
45. Re: DeGeorge et al. Outcomes and complications of operative versus non-operative management of distal radius fractures in adults under 65 years of age. J Hand Surg Eur. 2020, 46: 159–66
46. Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL).
47. Impact of Organ Function–Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?
48. Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience
49. Relapsed / Refractory International Prognostic Index (R/R-IPI):An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma
50. Relapsed/Refractory International Prognostic Index (R/ R‐IPI ): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.